PDCD1 and urothelial carcinoma: Accordingly, in earlier clinical trials the anti-PD-1 antibodies Nivolumab and Pembrolizumab had already been proven effective in treatments of melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer [10,11,12,13,14], while anti-PD-L1 antibodies, such as Atezolizumab, Avelumab, Durvalumab—have been proven effective in treatments of NSCLC, urothelial carcinoma, and triple negative breast cancer [15,16,17,18].